BioSkryb Genomics Launches ResolveOME Early Access Program for Full Genome and Transcriptome Amplification from a Single Cell, in Conjunction with Its Innovative Bioinformatics Platform, BaseJumperTM
- BioSkryb launches an exclusive Early Access Program at AGBT 2022 for ResolveOME and BaseJumper, a bioinformatics platform to accelerate single-cell exploration
- The company also recently released key data demonstrating how ResolveOME allows for the accurate assessment of single nucleotide genome scale plasticity in conjunction with transcriptional profiles
DURHAM, N.C., May 31, 2022--(BUSINESS WIRE)--BioSkryb Genomics, a biotech company developing advanced single-cell analysis tools, today announced the launch of the Early Access Program (EAP) for ResolveOME, a unified, single-cell workflow that amplifies the complete genome and full-length mRNA transcripts of the entire transcriptome from the same cell. This unification eliminated the need to split source material or interpret across datasets. Companies and researchers will have the opportunity to applyfor the EAP at the upcoming Advances in Genome Biology and Technology (AGBT) 2022 General Meeting taking place June 6-9 in Orlando. The EAP will provide first access to BioSkryb’s ResolveOME technology and BaseJumper, a bioinformatics platform to sort, analyze, and interpret very large single-cell analysis data sets.
“The ability to deeply understand the factors influencing cell heterogeneity is key to unlocking insights into disease and developing new drugs and diagnostics,” said Jay A.A. West, PhD, CEO and Cofounder of BioSkryb. “We developed ResolveOME to deliver multiple tiers of dynamic molecular information to drive novel biological insights and deliver a more complete understanding of the relationship between genotype to phenotype.”
BioSkryb recently released data demonstrating the use of ResolveOME to explore genetic drivers of tumor heterogeneity and treatment resistance. Employing even a relatively small number of individual cells ResolveOME has elucidated biomarkers of cellular variability in both the genome and transcriptome. The study highlights that both the genome and transcriptome are dynamic and plastic within individual cells, leading to a set of combinatorial alterations that affect cellular evolution. ResolveOME enables the unification of broad genomic and transcriptomic data from the same cell, driving a new understanding of the mechanisms of cellular function and differentiation.
“While we are thrilled with the performance of the ResolveOME chemistry system, what continues to surprise us is the incredible plasticity of the genome, compared to the transcriptome. In addition, using full-length mRNA transcriptional profiles from the same cells, we are able to discern the biological impact, or penetrance, of these genome modifications. Discovering genomic variation in the absence of information about transcriptional consequence of that plasticity or, conversely, a transcriptional signature without understanding underlying genomic contributions, hinders the
understanding of the molecular mechanisms of disease,” explained Dr. West. “ResolveOME provides a previously unattainable expansion of data capture and resolution, providing insights into tumor phenotype, immune evasion, and drug resistance which we expect will transform cancer drug discovery and development.”
BioSkryb’s ResolveOME and ResolveDNA TM products incorporate proprietary primary template-directed amplification (PTA) technology, which was created to address the inherent challenges of single-cell genomics by producing high-quality gene sequencing data. PTA technology employs controlled reaction parameters to uniformly amplify >95% of the genomes of single cells and low-
input samples with high precision and sensitivity, resulting in the highest quality analyses available today for any single-cell genomic applications.
“In addition to being the first to access ResolveOME, EAP partners will be enabled to leverage BaseJumper, which links a cell’s identity and genotype to identify and interpret molecular variability,” said Gary Harton, PhD, Chief Scientific Officer of BioSkryb. “While both ResolveDNA and Resolve provide an order of magnitude of improvement in sensitivity over conventional bulk sequencing methods, BaseJumper provides the ability to visualize the data in an intuitive layout which accelerates discoveries from single-cell genomics.”
During AGBT 2022, BioSkryb scientific experts will be available in the Manatee Suite, located on the lower level of Signia by Hilton Orlando Bonnet Creek. A limited number of private BaseJumper demonstrations are available and can be reserved by emailing info@bioskryb.com.
About BioSkryb Genomics
BioSkryb Genomics is a venture-backed developer of genomic amplification technologies. BioSkryb develops single-cell whole genome amplification tools to study genomic heterogeneity aiding researchers and companies in the discovery of novel insights into human disease at the cellular level. BioSkryb is headquartered in Durham, North Carolina. For more information, visit
www.bioskryb.com.
Company Contact: Company Contact: Gary Harton, PhD, CSO, BioSkryb, info@bioskryb.com, +1.919.370.0841 Media Contact: Jessica Yingling, PhD, Little Dog Communications Inc., jessica@litldog.com,
+1.858.344.8091
BioSkryb Genomics and ALS Automated Lab Solutions GmbH Sign U.S. Distribution Agreement to Power Unprecedented Single Cell Spatial Genomics
- The agreement combines industry-leading technologies, enabling single cell selection and genome sequencing, and supports the development of intact tissue sample analysis
- Together these technologies are designed to deliver breakthrough insights into in situ cellular heterogeneity to drive disease research, diagnostic and drug development, and treatment decisions
February 08, 2022 08:00 AM Eastern Standard Time
DURHAM, N.C.--(BUSINESS WIRE)--BioSkryb Genomics, a leader of single-cell genome amplification, and ALS Automated Lab Solutions GmbH, developers of a multi-patented spatial single cell and colony picking technology platform, today announced a U.S. distribution agreement to power comprehensive single cell plus spatial genomic analysis. The agreement was signed in December 2021. In addition, the partnership will develop single-cell genome analysis from intact tissue samples. The distribution agreement combines BioSkryb’s proprietary ResolveDNA™ technology with ALS CellCelector™ platform to drive single-cell genomic applications where the genome context matters.
Traditional “bulk” sequencing methods combine all cells of a tissue sample (e.g., a cancer biopsy) before sequencing and have persisted primarily due to the lack of quality DNA amplification from a single cell. Now with BioSkryb’s proprietary ResolveDNA technology combined with ALS CellCelector platform, researchers and clinicians can perform single-cell genomics from cells isolated at a specific location. The companies are collaborating to extend analysis of intact tissue specimens, where a single cell is selected from the organized cell structure and analyzed with high resolution genome analysis. This process is designed to maintain the cell context of their original environment and provides critical information for many fields, including oncology, cardiology, neurology, immunology, and preimplantation genetic testing, that could help guide diagnostics and treatment decisions.
“This will be a breakthrough for researchers and clinicians, and eventually for patients, because in one experiment, we will be able to achieve high resolution single-cell omics of critical cells, while retaining the context of where those cells interact with other cells and critical landmarks within the tissue sample,” said Jay West, Ph.D., CEO and Cofounder of BioSkryb. “With this expanded distribution agreement between BioSkryb and ALS, we will be offering an understanding of the ‘micro’ with the ‘macro” that can help accelerate genomic insights in the fields of pathology, diagnostics, and drug discovery, that can ultimately improve patient care.”
Jens Eberhardt, CEO and Cofounder of ALS added, “With this collaboration, we will enable researchers to benefit from the best in both worlds – market leading single cell isolation technology and best-in-class single cell analysis know-how and reagents. With this combined experience, we will be able to speed up knowledge and understanding of researchers and scientists that will ultimately benefit the patients soon.”
BioSkryb’s ResolveDNA products incorporate proprietary primary template-directed amplification (PTA) technology, which was created to address the inherent challenges of single-cell genomics by producing high-quality gene sequencing data. PTA technology employs controlled reaction parameters to reproducibly recover >95% of the genomes of single cells and low-input samples with high accuracy and uniformity. ResolveDNA products support sequencing library generation produced from limiting samples that have undergone whole genome amplification, resulting in the highest quality genetic analyses available today for many single-cell genomic applications.
BioSkryb Genomics will be launching an Early Access Program (EAP) for researchers to acquire the combined ALS CellCelector and ResolveDNA workflow. For more information, please visit: https://www.bioskryb.com/eap-cellcelector/
About ALS Automated Lab Solutions GmbH
ALS Automated Lab Solutions develops, manufactures and sells high-quality automated solutions for life sciences in a broad range of areas including molecular diagnostics, cancer and stem cell research, cell line development and bioprocessing. The company's core competencies are in automated cell manipulation, cell sorting and isolation, microscopic high-content imaging and analysis as well as liquid handling. The ALS CellCelector™ is the world's leading single cell and colony picking platform and is based on a multi-patented, unique cell and colony isolation technology which provides unmatched flexibility, high-quality results, operational reliability, cost-effectiveness and simple use. ALS Automated Lab Solutions GmbH is headquartered in Jena, Germany. For more information, visit www.als-jena.com.
About BioSkryb Genomics
BioSkryb Genomics is a venture-backed developer of genomic amplification technologies. BioSkryb develops single-cell whole genome amplification tools to study genomic heterogeneity and enable the development of new diagnostics for insights into human disease at the cellular level. BioSkryb is headquartered in Durham, North Carolina For more information, visit www.bioskryb.com.
Company Contact: Jaione Maiz, Business Development, info@bioskryb.com, +1.919.370.0841
Media Contact: Jessica Yingling, Ph.D., Little Dog Communications, jessica@litldog.com, +1.858.344.8091
BioSkryb Completes Move into New Global Headquarters in Durham, N.C.
Move supports company’s multi-year strategic growth initiative; advances retention, attraction, and expansion of the team; enhances the ability to serve customers; and demonstrates Company's commitment to the region
DURHAM, N.C., October 12, 2021 – BioSkryb Genomics, Inc., today announced the relocation and expansion of its corporate headquarters and research center in Durham, N.C. to advance the growth and operations of the company. BioSkryb develops single-cell whole genome amplification tools to study genomic heterogeneity and enable the development of new diagnostics for insights into human disease at the cellular level.
“This move into a larger, modern space represents the recent growth of the company and our plans to continue expansion of our team of dedicated researchers, engineers, and highly-skilled personnel to support product development, sales, and service,” said Rob Kaizerman, Chief Operating Officer of BioSkryb Genomics. “By bringing the BioSkryb team together under one roof, we can better deliver on our commitment to developing and delivering high resolution research tools and clinical diagnostics for cancer genomics, preimplantation genetic testing, and other applications.”
The 19,500-square-foot headquarters and innovation space, located in Durham, provides a modern workspace designed for collaboration and company growth. The innovation space includes all new equipment and facilities to support BioSkryb’s new product R&D, in-house testing services, product manufacturing and packaging, and quality control. BioSkryb plans to double its current workforce by the end of next year to a total of 50 highly skilled professionals, including genetic researchers, chemists, software engineers and developers, program managers, and quality control personnel.
“This new facility not only provides us an opportunity to grow our team but also deliver higher innovation to our customers, as we give them an unparalleled view of the specific genetic changes at the cellular level that are driving disease,” said Jay West, Ph.D., CEO and cofounder of BioSkryb Genomics. “Whether customers use our ResolveDNA products in their own lab or have our team analyze samples at our facility, we provide an unprecedented resolution of genomic heterogeneity so researchers and clinicians can understand genetic diversity at the single-cell level and make transformative discoveries to improve human health.”
BioSkryb’s Primary Template-directed Amplification (PTA) technology is a novel whole genome amplification approach that amplifies the genomes of single cells in a more accurate, uniform, and reproducible manner than previous methods. The Company’s ResolveDNA product line accurately and uniformly reproduce genomes of single cells to provide high-quality, scalable analysis of single-cell genomic heterogeneity. The company also has an end-to-end workflow solution, including BaseJumper, a cloud-based bioinformatics platform that allows users to explore single-cell human genomic datasets generated with ResolveDNA products.
About BioSkryb
BioSkryb Genomics is a venture-backed developer of genomic amplification technologies based in Durham, North Carolina. The Company’s proprietary Primary Template-directed Amplification (PTA) system delivers reproducible, high coverage breadth, and uniformity for various low or ultra-low input sequencing applications. BioSkryb’s solutions support sequencing library generation produced from limiting samples that have undergone whole genome amplification, resulting in the highest quality genetic analyses available today. For more information, please visit: www.bioskryb.com.
Company Contact: Rob Kaizerman, rob.kaizerman@bioskryb.com, +1.919.370.0841
Media Contact: Jessica Yingling, Ph.D., Little Dog Communications, jessica@litldog.com, +1.858.344.8091
Meet BioSkryb's New Commercial Team Members
We are excited to welcome three new team members who bring deep scientific knowledge as well as technical experience in supporting researcher needs in applying new genomic and molecular biology solutions.
“Just as we know each cell is unique, so are our people,” said Jay West, Ph.D., CEO and cofounder of BioSkryb. “Here we want to tell the stories of our new team members because their unique backgrounds and dedication to this space are what will ultimately help our customers uncover the untold story of each cell to enable a new world of individualized answers.”
Jill Waters is an accomplished scientist with more than 15 years of next generation sequencing (NGS) experience and was most recently a Field Application Scientist at Genapsys. She started her NGS career in single cell genomics when less than a handful of labs around the world had knowledge of the space. Her background in early R&D and cutting-edge, blue-sky technology informs her creative approach to supporting customers on the field applications side of science.
“Over 15 years ago, when single cell genomics was first born, we saw a gap in obtaining both SNV and CNV data from the same WGA technique, so I am excited to join and support BioSkryb, who has finally filled that gap with their PTA technology,” said Jill.
BioSkryb’s Primary Template-directed Amplification (PTA) technology is a novel whole genome amplification approach that amplifies the genomes of single cells in a more accurate, uniform, and reproducible manner than previous methods. PTA accurately calls variants in genomes and reproducibly captures more than 95% of the genomes of single cells in a more consistent and accurate manner than existing approaches.
Jennifer Van Fleet has more than 15 years of biotech industry experience in sales and account management and most recently supported NGS products as a Senior Genomic Solutions Specialist at Roche. Her career has been dedicated to developing strong collaborative relationships with researchers.
Jennifer said, “I am excited to join Bioskryb to work with a dedicated and driven team to provide accurate tools for single cell analysis that will enable improved health outcomes.”
Sofía De León Tobal, Ph.D., has been in technical sales for nearly 10 years for Integrated DNA Technologies. Sofia has a Ph.D. in biochemistry from Temple University and held a postdoctoral fellowship at Albert Einstein College of Medicine.
“I am excited to be working for a company that is committed to improving the single cell genomics world,” said Sofía. “At BioSkryb, there’s a commitment to higher service and innovation, and the team is hardworking, dedicated, and overall fantastic to work with.”
If you have a project that you think can benefit from our PTA technology and our experience, contact us here.
About BioSkryb
BioSkryb is a venture-backed developer of genomic amplification technologies based in Durham, North Carolina. Their proprietary Primary Template-directed Amplification (PTA) system delivers reproducible, high coverage breadth, and uniformity for various low or ultra-low input sequencing applications. BioSkryb’s solutions support sequencing library generation produced from limiting samples that have undergone whole genome amplification, resulting in the highest quality genetic analyses available today.
July 31 - Huatai Zhi made (MGI), IDG investment Innovation Institute and Blue Rainbow Life Sciences Accelerator jointly organized by the MGI & IDG capital accelerated life and health business (hereinafter referred to as "accelerated Camp") in the Nanshan District, Shenzhen, IDG Capital Innovation the Investment Research Institute officially opened.
At the opening ceremony of the accelerating camp, eight projects were disclosed for the first time, and the first core course of entrepreneurship was started. It is hoped that the accelerating camp will deeply empower start-ups and help them accelerate their growth.
This year's acceleration camp ushered in a new upgrade of industry and capital, and industry and leading institutions have joined forces. Relying on the sponsor's brand influence and industrial resource advantages, Accelerator will use industry resources to provide investment and all-factor incubation services for start-ups, and provide more powerful acceleration assistance. This accelerating camp received a total of more than 100 applications for projects at home and abroad. The organizer passed careful evaluation and selected the best, and finally selected 8 projects to enter the camp and one Project X. The application projects cover molecular diagnostics, cell therapy, and microbiology. Omics, single-cell omics, early tumor screening, AI drug development, organoids, synthetic biology, etc. In addition, in order to better answer questions and answer questions in the project, this year's acceleration camp also equips each project with 1V1 entrepreneurial mentors to help them complete their growth from 0 to 1.
At the beginning of the event, three representatives of the organizers gave the
opening speeches for the acceleration camp in turn. Zhao Weiwen, Executive President of Blue Rainbow Life Science Accelerator and Managing Partner of Miracle Light Venture Capital Fund, gave a speech first, expressing welcome to the founders of participating projects, and reviewed the operation process of the acceleration camp and the results of incubation investment. Through the two-wheel drive model of investment and incubation, Blue Rainbow has cultivated more than 150 high-end compound innovative and entrepreneurial talents in the life and health field through the acceleration camp as the cultivation carrier, and has helped nearly 50 life science start-up projects to grow rapidly in the early stage of entrepreneurship. The cumulative project valuation exceeds 10 billion. At the same time, it is hoped that in the coming camp period, the newly upgraded accelerating camp can link to a wider range of resources and help start-ups to accelerate their growth through all-factor incubation services.
Fang Xiao, general manager of MGI China, looked back and looked forward to the rapid development of MGI. He said that MGI’s scientific research innovation and technological development are very fast, and it has gradually transitioned from a tool platform to an ecological platform empowered by domestic platforms. The industry is booming. MGI is also willing to promote Chinese bio-enterprises to enter the global market faster through collaborative innovation. Fu Wenbo, general manager of IDG Innovation and Investment Research Institute, hopefully introduced the positioning and development of IDG Capital Innovation and Investment Research Institute, and referred to the acceleration camp as the cell's power plant "mitochondria". , in this factory that continuously provides ATP energy, the acceleration camp will be accelerated. Partners can create collisions and inspire inspiration through geographical and ideological connections. Afterwards, three representatives of the organizers awarded medals for the entry project, officially starting this accelerated camp tour.
In view of the development characteristics of the life science industry, the actual needs of start-up projects, and the challenges of each stage of the growth cycle, Accelerated Camp has carefully designed entrepreneurial core courses for entry projects. This year's entrepreneurial core curriculum covers five modules, covering macro trends and strategic layout, financing strategies and response, product development and production and marketing, fiscal and taxation law planning and patent layout, talent recruitment and brand building.
The first core course on entrepreneurship was also officially launched. Six entrepreneurial tutors led entrepreneurs to better carry out project strategic layout and "point" thinking around the "Macro Trends and Strategic Layout" module. Zhao Weiwen, CEO of Blue Rainbow Life Science Accelerator and Managing Partner of Miracle Light Venture Capital Fund, firstly brought "Entrepreneurship 101: The Easiest Thing in Entrepreneurship", citing Sun Tzu's "Tao Tiandi General Law" analysis to influence the success of startups the five factors of the ancient military strategy are applied to the management of modern start-ups; through the analysis of multiple real cases, it has clarified which key content will affect the success or failure, and can be controlled by the founder, and also pave the way for the follow-up acceleration camp courses. Liu Yikun, Managing Director of IDG Capital, analyzed the characteristics and trends of the biomedical industry from the perspective of investors. He emphasized that the innovation capability of China's biomedical industry is gradually improving. Only high-barrier innovative technologies and products, a platform-based industrial layout, and an international pattern and vision can have a chance to win in the fiercely competitive market in the future. Mao Jingyi, Head of Compliance of Yuce Biotechnology and Chairman of the Board of Supervisors, brought "Planning and Selection of Funding Channels for Start-ups", and by comparing the characteristics of different financing models, analyzing the difficulties and easy points of various financing schemes, and teaching SMEs "tailor-made" financing The way. Yang Danning, a partner of Probe Capital and CEO of Victory Consulting, Only shared a guide for writing and using business plans by building a business plan with "soul, skeleton and flesh and blood" can we better capture investors' attention. Cao Xiaoyu, the chief lawyer of Victory Consulting , analyzed the core elements that affect the smoothness of financing negotiations around the three negotiation dimensions of "rivals, information, and principles", and explained in detail the core terms of investment agreements, bringing entrepreneurs the skills and methods of investment negotiations. Dai Minghan, the investment director of Miracle Light Venture Capital Fund, explains investors' background research methods and communication skills to help entrepreneurs better choose investors for suitable projects and establish good trust relationships with investors.
At the opening of the camp, the organizer also arranged a unique icebreaking team-building activity, aimed at breaking the campers' diaphragm and creating a relaxed and harmonious team atmosphere. It is reported that in the follow-up to the acceleration camp, there will be a number of customized home games that will be launched one after another to provide diversified guidance and services for the entry projects. I also look forward to encountering the possibilities during this trip to the acceleration camp and colliding more sparks! Please stay tuned to the Blue Rainbow official account for more information on activities and courses.
Introduction to Entry Projects
Project 1. With rich clinical resources and cell therapy experience, we are committed to the research and development and industrialization of innovative solid tumor infiltrating lymphocytes (TIL) drugs.
Project 2. Relying on the technical platform of a national-level microbiological research institution, the project established a full-chain technology platform from bacteria to medicine from high-throughput anaerobic bacteria screening, functional identification to drug production. The company's first drug has been approved by the IND.
Project 3. The project independently developed the world's leading nucleic acid-free extraction technology CLIP-PCR. The company uses this technology as the core to provide molecular diagnostic reagent products and molecular diagnostic intelligent equipment and services.
Project 4. The project has PTA (Primary Template-directed Amplification) single-cell whole genome amplification technology, which provides high-yield, high-fidelity, high-uniformity, and high-reproducibility for single-cell whole-genome analysis Of amplification. This technology is also suitable for application scenarios where the initial amount of nucleic acid is very low.
Project 5. Based on the cohort study of Canada's largest pregnant research population, focusing on the discovery of biomarkers of preterm birth and the development of corresponding kits for screening people at risk of preterm birth and reducing the risk of preterm birth.
Project 6. The project has a million-level RNA molecular library and a multi-billion-level virtual library of small molecule compounds. Through transcriptome data and artificial intelligence technology, it provides computer drug screening for innovative drug research and development, drug property prediction, etc., as well as targeting the transcriptome data predicts small molecule drugs.
Project 7. The company has a unique high-throughput chip platform and analysis technology that "perfectly" integrates with organoids, which can quickly, accurately, and digitally assist the development of anti-tumor drugs and precision treatment, which is expected to bring about a revolution in new drug research and development change.
Project 8. The company has a unique synthetic biology and antigen discovery platform that can rationally design and reprogram pathogenic bacteria, so as to develop next-generation vaccines and live bacteria drugs to meet global public health security challenges.
BioSkryb Appoints Gary Harton, Ph.D., Chief Scientific Officer
Dr. Harton to lead the translation of BioSkryb’s Primary Template-directed Amplification (PTA) technology into breakthrough diagnostic applications for targeted indications, including cancer and neurological disorders
DURHAM, N.C., June 30, 2021 -- BioSkryb, Inc., today announced the expansion of the company’s leadership team with the appointment of Gary Harton, Ph.D., as Chief Scientific Officer. He has more than 30 years of experience in single cell diagnostic product development across all stages including R&D, reagent manufacturing, finance, sales, and marketing. At BioSkryb, Dr. Harton will apply BioSkryb’s platform technology and cumulative knowledge to develop new diagnostic technologies for cancer, neurological disorders, and assisted reproductive technologies to improve analysis and interpretation of complex genetic data and provide more detailed diagnostic information that can better inform treatment options.
BioSkryb’s Primary Template-directed Amplification (PTA) technology is a novel whole genome amplification approach that amplifies the genomes of single cells in a more accurate, uniform, and reproducible manner than previous methods. PTA accurately calls variants in genomes and reproducibly captures more than 95% of the genomes of single cells in a more consistent and accurate manner than existing approaches.
“Accurate whole genome amplification of single-cells is key to understanding, diagnosing, and treating human diseases involving genomic heterogeneity, like cancer,” said Jay West, Ph.D., CEO and cofounder of BioSkryb. “We are excited to have Gary join BioSkryb Genomics to extend our PTA based innovation pipeline and focus his efforts on developing new diagnostic technologies to better inform treatment decisions in cancer, neurology, and in vitro fertilization.”
Whole genome amplification (WGA) is required for low-input DNA and single-cell analysis, but current WGA technologies only cover a fraction of the genome and have a limited capacity to detect genetic variation in each cell. BioSkryb presented data at ASHG 2020 demonstrating the use of PTA technology to study genetic variants that drive therapeutic resistance in acute myeloid leukemia and triple-negative breast cancer.
Dr. Harton said, “Having spent my career in and around preimplantation genetics and non-invasive prenatal testing using single to low cell number samples, BioSkryb is a natural fit for me as the company’s platform technology is built to interrogate single cells and deliver an amazing quality and quantity of data. The ability to understand genetics, at the cellular level, can enable scientists and clinicians an unparalleled view of the genome and the specific changes that are driving disease and are relevant for therapeutic intervention.”
Prior to BioSkryb, Dr. Harton was the Portfolio Director, Preimplantation Genetic Testing responsible for Perkin Elmer’s new preimplantation genetic testing product line. In his career of 30-plus years specifically in diagnostic companies and laboratories, Dr. Harton has held a variety of positions leading product and portfolio development at Perkin Elmer, Igenomix US, Progyny, Illumina, BlueGnome Limited, and Reprogenetics. He has also been an author on numerous peer-reviewed scientific articles, abstracts, and book chapters and holds several part-time teaching positions in the US and abroad.
About BioSkryb
BioSkryb is a venture-backed developer of genomic amplification technologies based in Durham, North Carolina. Their proprietary Primary Template-directed Amplification (PTA) system delivers reproducible, high coverage breadth, and uniformity for various low or ultra-low input sequencing applications. BioSkryb’s solutions support sequencing library generation produced from limiting samples that have undergone whole genome amplification, resulting in the highest quality genetic analyses available today. For more information, please visit: www.bioskryb.com.
Company Contact: Gary Harton, Ph.D., gary.harton@bioskryb.com, +1.919.370.0841
Media Contact: Jessica Yingling, Ph.D., Little Dog Communications, jessica@litldog.com, +1.858.344.8091
Keohane to spearhead commercialization of BioSkryb’s ResolveDNATM suite of products for high-quality single-cell whole genome amplification
DURHAM, N.C.--(BUSINESS WIRE)--BioSkryb, Inc., today announced the expansion of the company’s leadership team with the appointment of Sean Keohane as Senior Vice President of Commercial Operations. Keohane has more than 25 years of experience in life science product commercialization, with demonstrated success in building strong teams and implementing strategic plans to capture market share and profit growth. At BioSkryb, Keohane will grow and lead the sales and marketing team to commercialize the Company’s product and service offerings, which incorporates novel Primary Template-directed Amplification (PTA) technology.
“From large to small solution provider companies, Sean has extensive experience in building, leading, and growing successful sales teams that deliver results,” said Jay West, Ph.D., CEO, and cofounder of BioSkryb. “We are excited to have Sean join BioSkryb as we grow the company and expand commercialization of our first suite of products that are capable of powering the exploration of new genomic frontiers.”
The BioTech industry is adopting trends like artificial intelligence (AI), data analytics, and automation to optimize production. Consequently, there has been a rise in consumer BioTech or BioTech products targeted directly at customers instead of biopharma or healthcare businesses. While the industry largely still focuses on medicine, startups are working on solutions ranging from food and materials to environmental monitoring. The COVID-19 pandemic really highlighted the far-reaching impact of the BioTech industry, with startups and companies alike developing rapid testing kits, repurposed drugs, and vaccines.
Innovation Map: Top 10 Biotech Trends & Innovations
Covering more than 1.139.000 startups & emerging companies, we use our proprietary StartUs Insights Discovery Platform to identify innovative applications and solutions that will impact the BioTechnology sector in 2021. Our Innovation Analysts conducted exhaustive data-driven research to identify the various innovation trends and technologies emerging in BioTech. For this research, we analyzed 4.351 startups and emerging companies and present the Top 10 BioTech Trends along with 20 highly relevant solutions for each of them.
The Innovation Map below visualizes the major BioTech trends that impact the sector and showcase two hand-picked startups for each trend.
DURHAM, N.C.--(BUSINESS WIRE)--Today, at the Advances in Genome Biology and Technology (AGBT) 2021 General Meeting held virtually, BioSkryb, Inc., a developer of genomic amplification technologies, announced the winners of a research grant program sponsored by the company. The grant program was created to accelerate innovation of single-cell genomic studies using the primary template-directed amplification (PTA) technology developed by BioSkryb and now commercially available as ResolveDNA™.
“We found it extremely inspiring that all of the applicants demonstrated a level of creativity, expertise, and commitment to advancing genomic research that deserved recognition”
The recipients of the BioSkryb research grants are:
- Dr. Joseph Gleeson, Rady Professor, UCSD Department of Neurosciences, University of California, San Diego and Rady Children’s Institute for Genomic Medicine
- Dr. Shao-bin Wang, Assistant Professor of Ophthalmology, University of Virginia School of Medicine and UVA’s Center for Advanced Vision Science
DURHAM, N.C.--(BUSINESS WIRE)--BioSkryb, Inc., a developer of genomic amplification technologies, today announced the launch of a research grant program sponsored by the company to accelerate innovation of single-cell genomic studies using its primary template-directed amplification (PTA) technology, now commercially available as the ResolveDNA™ suite of products. The program will support two researchers, each awarded a grant worth up to $20,000, for demonstrating that their research can fuel new discoveries in single-cell genomics and have a positive impact upon improving human health.